Kurs
-2,03%
Likviditet
171 MDKK
Kalender
| Est. tid* | ||
| 2025-12-04 | N/A | Årsstämma |
| 2025-11-04 | 12:10 | Bokslutskommuniké 2025 |
| 2025-08-19 | 07:30 | Kvartalsrapport 2025-Q3 |
| 2025-05-06 | - | Kvartalsrapport 2025-Q2 |
| 2025-02-04 | - | Kvartalsrapport 2025-Q1 |
| 2024-12-06 | - | X-dag halvårsutdelning COLO B 17 |
| 2024-12-05 | - | Årsstämma |
| 2024-11-05 | - | Bokslutskommuniké 2024 |
| 2024-08-20 | - | Kvartalsrapport 2024-Q3 |
| 2024-05-13 | - | X-dag halvårsutdelning COLO B 5 |
| 2024-05-07 | - | Kvartalsrapport 2024-Q2 |
| 2024-02-09 | - | Kvartalsrapport 2024-Q1 |
| 2023-12-08 | - | X-dag halvårsutdelning COLO B 16 |
| 2023-12-07 | - | Årsstämma |
| 2023-11-09 | - | Bokslutskommuniké 2023 |
| 2023-08-17 | - | Kvartalsrapport 2023-Q3 |
| 2023-05-15 | - | X-dag halvårsutdelning COLO B 5 |
| 2023-05-11 | - | Kvartalsrapport 2023-Q2 |
| 2023-02-03 | - | Kvartalsrapport 2023-Q1 |
| 2022-12-02 | - | X-dag halvårsutdelning COLO B 15 |
| 2022-12-01 | - | Årsstämma |
| 2022-11-07 | - | Bokslutskommuniké 2022 |
| 2022-08-17 | - | Kvartalsrapport 2022-Q3 |
| 2022-05-09 | - | X-dag halvårsutdelning COLO B 5 |
| 2022-05-05 | - | Kvartalsrapport 2022-Q2 |
| 2022-01-25 | - | Kvartalsrapport 2022-Q1 |
| 2021-12-03 | - | X-dag halvårsutdelning COLO B 14 |
| 2021-12-02 | - | Årsstämma |
| 2021-11-01 | - | Bokslutskommuniké 2021 |
| 2021-08-18 | - | Kvartalsrapport 2021-Q3 |
| 2021-05-10 | - | X-dag halvårsutdelning COLO B 5 |
| 2021-05-06 | - | Kvartalsrapport 2021-Q2 |
| 2021-02-06 | - | Kvartalsrapport 2021-Q1 |
| 2020-12-04 | - | X-dag halvårsutdelning COLO B 13 |
| 2020-12-03 | - | Årsstämma |
| 2020-11-03 | - | Bokslutskommuniké 2020 |
| 2020-08-18 | - | Kvartalsrapport 2020-Q3 |
| 2020-05-11 | - | X-dag halvårsutdelning COLO B 5 |
| 2020-05-06 | - | Kvartalsrapport 2020-Q2 |
| 2020-02-06 | - | Kvartalsrapport 2020-Q1 |
| 2019-12-06 | - | X-dag halvårsutdelning COLO B 12 |
| 2019-12-05 | - | Årsstämma |
| 2019-11-05 | - | Bokslutskommuniké 2019 |
| 2019-08-14 | - | Kvartalsrapport 2019-Q3 |
| 2019-05-06 | - | X-dag halvårsutdelning COLO B 5 |
| 2019-05-02 | - | Kvartalsrapport 2019-Q2 |
| 2019-02-05 | - | Kvartalsrapport 2019-Q1 |
| 2018-12-06 | - | X-dag halvårsutdelning COLO B 11 |
| 2018-12-05 | - | Årsstämma |
| 2018-11-01 | - | Bokslutskommuniké 2018 |
| 2018-08-08 | - | Kvartalsrapport 2018-Q3 |
| 2018-05-07 | - | X-dag halvårsutdelning COLO B 5 |
| 2018-05-03 | - | Kvartalsrapport 2018-Q2 |
| 2018-02-01 | - | Kvartalsrapport 2018-Q1 |
| 2017-12-08 | - | X-dag halvårsutdelning COLO B 10.5 |
| 2017-12-07 | - | Årsstämma |
| 2017-11-02 | - | Bokslutskommuniké 2017 |
| 2017-08-16 | - | Kvartalsrapport 2017-Q3 |
| 2017-05-08 | - | X-dag halvårsutdelning COLO B 4.5 |
| 2017-05-03 | - | Kvartalsrapport 2017-Q2 |
| 2017-02-01 | - | Kvartalsrapport 2017-Q1 |
| 2016-12-06 | - | X-dag halvårsutdelning COLO B 9 |
| 2016-12-05 | - | Årsstämma |
| 2016-11-02 | - | Bokslutskommuniké 2016 |
| 2016-08-16 | - | Kvartalsrapport 2016-Q3 |
| 2016-05-09 | - | X-dag halvårsutdelning COLO B 4.5 |
| 2016-05-03 | - | Kvartalsrapport 2016-Q2 |
| 2016-02-02 | - | Kvartalsrapport 2016-Q1 |
| 2015-12-10 | - | X-dag halvårsutdelning COLO B 8 |
| 2015-12-09 | - | Årsstämma |
| 2015-11-03 | - | Bokslutskommuniké 2015 |
| 2015-08-11 | - | Kvartalsrapport 2015-Q3 |
| 2015-05-07 | - | X-dag halvårsutdelning COLO B 4.5 |
| 2015-05-05 | - | Kvartalsrapport 2015-Q2 |
| 2015-01-29 | - | Kvartalsrapport 2015-Q1 |
| 2014-12-05 | - | X-dag halvårsutdelning COLO B 7.5 |
| 2014-12-04 | - | Årsstämma |
| 2014-10-30 | - | Bokslutskommuniké 2014 |
| 2014-05-08 | - | X-dag halvårsutdelning COLO B 4 |
| 2013-12-06 | - | X-dag halvårsutdelning COLO B 7 |
| 2013-12-05 | - | Årsstämma |
| 2013-10-31 | - | Bokslutskommuniké 2013 |
| 2013-08-13 | - | Kvartalsrapport 2013-Q3 |
| 2013-05-06 | - | X-dag halvårsutdelning COLO B 3 |
| 2013-04-30 | - | Kvartalsrapport 2013-Q2 |
| 2013-01-30 | - | Kvartalsrapport 2013-Q1 |
| 2012-12-19 | - | Split COLO B 1:5 |
| 2012-12-11 | - | Årsstämma |
| 2012-11-06 | - | Bokslutskommuniké 2012 |
| 2012-08-15 | - | Kvartalsrapport 2012-Q3 |
| 2012-04-26 | - | Kvartalsrapport 2012-Q2 |
| 2012-01-25 | - | Kvartalsrapport 2012-Q1 |
| 2011-12-08 | - | X-dag ordinarie utdelning COLO B 14.00 DKK |
| 2011-12-07 | - | Årsstämma |
| 2011-11-01 | - | Bokslutskommuniké 2011 |
| 2011-08-17 | - | Kvartalsrapport 2011-Q3 |
| 2011-06-21 | - | Kapitalmarknadsdag 2011 |
| 2011-05-04 | - | Kvartalsrapport 2011-Q2 |
| 2011-01-26 | - | Kvartalsrapport 2011-Q1 |
| 2010-12-02 | - | X-dag ordinarie utdelning COLO B 10.00 DKK |
| 2009-12-02 | - | X-dag ordinarie utdelning COLO B 7.00 DKK |
| 2004-12-16 | - | Split COLO B 1:2 |
Beskrivning
| Land | Danmark |
|---|---|
| Lista | Large Cap Copenhagen |
| Sektor | Hälsovård |
| Industri | Medicinteknik |
Together with patient organizations, healthcare professionals and other groups, Coloplast has supported a project through the company’s Access to Healthcare programme advocating for better access to hydrophilic catheters for people living with neurogenic bladder dysfunction in Poland.
With the new scheme, the Polish Ministry of Health has decided to significantly improve reimbursement for hydrophilic catheters, bringing it on par with the European standard. It will impact thousands of people living with neurogenic bladder dysfunction such as spinal cord injured or children living with spina bifida.
“We are committed to raising the standard of care for people with intimate healthcare conditions around the world. I am pleased to see that more people with neurogenic bladder dysfunction in Poland will now get access to products that will enable them to lead full and dignified lives,” says Coloplast’s CEO Kristian Villumsen.
Using hydrophilic catheters instead of uncoated catheters, the current standard in Poland, is clinically proven to reduce the risk of urinary tract infections1 – a critical complication associated with catheterization. Coloplast looks forward to December 1st when the improved reimbursement takes effect and the transition to hydrophilic catheters begins.
“I admire the many different groups, from patient organizations to urologists, who have put in a persistent amount of work to raise awareness of what better catheterization means for quality of life. This is a breakthrough for the thousands of adults and children living with neurogenic bladder dysfunction. Now it is our task to ensure that the transition to hydrophilic catheters is backed with the right training and care,” says Hubert Niemyjski, Country Manager of Coloplast Poland.
To support a successful transition to hydrophilic catheters, Coloplast will focus on training healthcare professionals on the correct use of hydrophilic catheters. Coloplast will also place great emphasis on educating and supporting users through the Coloplast Care programme.
Coloplast’s Access to Healthcare programme was established in 2007 and aims to raise the standard of care, provide users with a voice, and advocate for better care and reimbursement with healthcare policy makers around the world.
1Rognoni and Tarricone BMC Urology (2017) 17:4
CONTACT
Peter Mønster
Senior Media Relations Manager, Corporate Communications
+45 49 11 26 23
dkpete@coloplast.com
